Fight Against Pancreatic Cancer: Participate in the PRECEDE Study
The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global initiative aiming to increase the 5-year survival rate for pancreatic cancer from 13% to 50% within the next 10 years. This collaborative effort focuses on improving early detection, screening, and prevention, particularly for those at high genetic risk.
Pancreatic cancer is one of the deadliest cancers, with few early symptoms and limited treatment options. The PRECEDE study aims to develop new tools for early detection, which could save countless lives. Participants are needed for a longitudinal study (takes place over several years) involving regular biosample collection and clinical data. Your involvement will contribute to accelerating breakthroughs in pancreatic cancer research.
The study is open to individuals in British Columbia with an identified BRCA1 or BRCA2 pathogenic variant and a family history of pancreatic cancer in a 1st or 2nd degree relative.
Participation in the study involves:
Completing an annual health questionnaire
Attending an annual imagining exam as ordered by your doctor
Providing a research blood sample drawn annually at Vancouver General Hospital
Note: The PRECEDE team does not organize screening. All screening is ordered by your family doctor or GI specialist.
To inquire or join the study, you can email eugene.cheung1@bccancer.bc.ca or phone 604-877-6000 ext. 673267.